Blood Advances

Papers
(The TQCC of Blood Advances is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism639
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer427
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19302
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma267
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease255
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma241
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma233
A neutrophil activation signature predicts critical illness and mortality in COVID-19222
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma202
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain184
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies168
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease158
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma139
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma136
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients127
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML125
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma123
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub119
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma118
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features118
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1116
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19114
Reduced prevalence of SARS-CoV-2 infection in ABO blood group O113
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults111
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia107
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML105
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations102
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT100
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma97
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-1996
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 95
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease94
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease94
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML92
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia92
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-1990
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience88
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML86
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge85
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure81
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura80
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data80
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial78
The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma77
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality77
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A76
Next-generation cell therapies: the emerging role of CAR-NK cells74
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study73
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis72
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma71
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients71
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation70
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma69
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease68
Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia68
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis67
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States67
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy66
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies65
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma64
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia64
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML64
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations63
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis63
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma63
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy62
Survival following allogeneic transplant in patients with myelofibrosis61
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study61
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells60
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial60
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity60
BiTEs better than CAR T cells60
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort60
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms60
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma60
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma59
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia59
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis59
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up59
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection59
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide59
Inflammasome activation in neutrophils of patients with severe COVID-1958
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial58
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia58
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities58
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects57
High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential57
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis57
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals55
Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match55
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas55
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome55
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents54
The incidence of cancer-associated thrombosis is increasing over time54
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells53
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma53
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults52
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-1952
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies52
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results52
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice51
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis51
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells51
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features50
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)50
Artificial intelligence–based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients50
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease50
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study50
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification50
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML49
Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity49
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data49
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial48
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles48
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis48
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy47
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm47
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination47
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients47
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells47
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy47
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes47
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant47
Lung megakaryocytes display distinct transcriptional and phenotypic properties47
Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma46
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy46
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP45
COVID-19 coagulopathy vs disseminated intravascular coagulation45
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients45
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase44
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication44
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma44
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells44
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP44
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-1943
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in43
Lingering effects of chemotherapy on mature T cells impair proliferation43
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?43
Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years43
Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation43
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy43
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML42
Development of luspatercept to treat ineffective erythropoiesis42
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide42
Cell interactions in the bone marrow microenvironment affecting myeloid malignancies42
Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects42
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis42
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes42
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings42
Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism42
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation42
Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients42
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia41
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma41
High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers41
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition41
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse41
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients41
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies41
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies41
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models41
Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice41
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma40
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma40
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure40
CAR T-cell therapy for secondary CNS DLBCL40
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma40
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms39
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation39
Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells39
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study39
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-1939
Mesenchymal stromal cells in hematopoietic cell transplantation39
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation39
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation39
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma39
Laboratory monitoring of hemophilia A treatments: new challenges39
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure38
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome38
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia38
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation38
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis38
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia38
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma38
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy38
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern38
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia37
Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions37
Suboptimal iron deficiency screening in pregnancy and the impact of socioeconomic status in a high-resource setting37
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO273437
Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes37
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia37
Inflammasome activation promotes venous thrombosis through pyroptosis37
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis37
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax37
First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG36
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia36
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium36
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia36
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance36
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors36
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer36
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity36
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-235
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant35
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up35
Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis35
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition35
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma35
OvCa-Chip microsystem recreates vascular endothelium–mediated platelet extravasation in ovarian cancer35
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases35
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation35
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia35
Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden35
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification35
Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial34
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-00134
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis34
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)34
Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era34
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission34
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report34
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study34
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients34
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents34
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery34
Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy34
Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM33
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation33
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses33
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia33
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial33
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma33
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis33
The evolution of factor XI and the kallikrein-kinin system33
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial33
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies32
Polarized mitochondria as guardians of NK cell fitness32
Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-1932
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome32
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-1932
Approach to the diagnosis of aplastic anemia32
Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets32
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma32
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study32
Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study32
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant32
Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy32
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML32
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML32
0.053098917007446